研究单位：[1]Jemincare[2]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,233004[3]Xuanwu Hospital, Capital Medical University,Beijing,Beijing,China,100053[4]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[5]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510080[6]The First Affiliated Hospital of Henan University of science and Technology,Luoyang,Henan,China,471003[7]Xinxiang Central Hospital,Xinxiang,Henan,China,453099[8]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[9]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[10]Pingxiang People's Hospital,Pingxiang,Jiangxi,China,337055[11]China-Japan Union Hospital of Jilin University,Changchun,Jilin,China,130033[12]Binzhou Medical University Hospital,Binzhou,Shandong,China,256603[13]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[14]Jining First People's Hospital,Jining,Shandong,China,272002[15]Huashan Hospital Affiliated to Fudan University,Shanghai,Shanghai,China,200040[16]Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China,200127[17]Shanxi Bethune Hospital,Taiyuan,Shanxi,China,030032[18]West China Hospital Sichuan University,Chengdu,Sichuan,China,610041
研究目的：
The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.
